【摘要】 目的：评价在标准止吐方案基础上，联合应用金复康口服液对非小细胞肺癌（NSCLC）术后辅助化疗患者化疗相关症状群（包括延迟性恶心呕吐、疲乏、食欲减退和进食量下降）的改善效果。方法：采用回顾性队列研究设计，收集2024年4月—2025年9月期间于本院接受NSCLC术后辅助化疗的126例患者的资料。根据治疗方案分为对照组（63例，接受标准化疗及标准止吐方案）和研究组（63例，在对照组治疗基础上加用金复康口服液）。分别用国际癌症支持治疗多国协会（MASCC）止吐评价工具（MAT）、简易疲乏量表（BFI）和食欲/进食量刻度尺评估两组患者在延迟性恶心呕吐、疲乏以及食欲与进食量方面的差异，并采用多元线性回归分析控制混杂因素。结果：两组患者基线特征均衡可比。与对照组相比，研究组患者的延迟性恶心呕吐及疲乏症状显著减轻[MAT评分1(1,1) vs 2(1,2),P<0.001;BFI评分1(1,1) vs 4(4,4),P<0.001]。在食欲与进食量方面，化疗后第7天，研究组评分显著高于对照组[食欲评分8(8,8) vs 2(2,2),P<0.001；进食量评分6(6,6) vs 3(3,3),P<0.001]，且较化疗后第1天呈上升趋势，对照组呈下降趋势。多元线性回归分析证实金复康口服液是症状改善的独立影响因素（均P<0.001）。结论：金复康口服液可显著改善NSCLC术后辅助化疗患者的延迟性恶心呕吐、疲乏、食欲减退及进食量下降症状群，提升生活质量。更多还原

【Abstract】 Objective: To evaluate the efficacy of Jinfukang oral liquid in improving chemotherapyrelated symptom clusters(including delayed nausea and vomiting, fatigue, and decreased appetite and food intake) in patients undergoing adjuvant chemotherapy after non-small cell lung cancer(NSCLC) surgery, based on a standard antiemetic regimen. Methods: A retrospective cohort study design was employed, collecting data from 126 patients who received adjuvant chemotherapy for NSCLC between April 2024 and September 2025. Patients were divided into a control group(63 cases, receiving standardized chemotherapy and a standard antiemetic regimen) and a study group(63 cases, receiving Jinfukang oral liquid in addition to the control group’s treatment). Differences in delayed nausea and vomiting, fatigue, and appetite/food intake were compared between the two groups using the MASCC Antiemesis Tool(MAT), Brief Fatigue Inventory(BFI), and Appetite/Food Intake Scale. Multivariate linear regression analysis was used to control confounding factors. Results: The baseline characteristics of the two groups were balanced and comparable. Compared to the control group, the study group showed significant improvement in delayed nausea and vomiting and fatigue symptoms(MAT score: 1(1, 1) vs 2(1, 2), P<0.001; BFI score: 1(1, 1) vs 4(4, 4), P<0.001). Regarding appetite and food intake, on day 7 post-chemotherapy, the scores of the study group were significantly higher than those of the control group(appetite score: 8(8, 8) vs 2(2, 2), P<0.001; food intake score: 6(6, 6) vs 3(3, 3), P<0.001), with a rising trend compared to day 1 postchemotherapy, while the control group showed a decline. Multivariate linear regression analysis further confirmed that Jinfukang oral liquid was an independent factor for symptom improvement(all P<0.001). Conclusion: Jinfukang oral liquid significantly improves symptom clusters such as delayed nausea and vomiting, fatigue, decreased appetite, and reduced food intake in NSCLC patients undergoing adjuvant chemotherapy after surgery, thereby enhancing quality of life.更多还原